Adenoviral vector tethering to metal surfaces via hydrolyzable cross-linkers for the modulation of vector release and transduction
Source abstract
Abstract
The use of arterial stents and other medical implants as a delivery platform for surface immobilized gene vectors allows for safe and efficient localized expression of therapeutic transgenes. In this study we investigate the use of hydrolyzable cross-linkers with distinct kinetics of hydrolysis for delivery of gene vectors from polyallylamine bisphosphonate-modified metal surfaces. Three cross-linkers with the estimated t1/2 of ester bonds hydrolysis of 5, 12 and 50 days demonstrated a cumulative 20%, 39% and 45% vector release, respectively, after 30 days exposure to physiological buffer at 37 °C. Transgene expression in endothelial and smooth muscles cells transduced with substrate immobilized adenovirus resulted in significantly different expression profiles for each individual cross-linker. Furthermore, immobilization of adenoviral vectors effectively extended their transduction effectiveness beyond the initial phase of release. Transgene expression driven by adenovirus-tethered stents in rat carotid arteries demonstrated that a faster rate of cross-linker hydrolysis resulted in higher expression levels at day 1, which declined by day 8 after stent implantation, while inversely, slower hydrolysis was associated with increased arterial expression at day 8 in comparison with day 1. In conclusion, adjustable release of transduction-competent adenoviral vectors from metallic surfaces can be achieved, both in vitro and in vivo, through surface immobilization of adenoviral vectors using hydrolyzable cross-linkers with structure-specific release kinetics.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Virus-based gene therapy research · RNA Interference and Gene Delivery · Viral Infectious Diseases and Gene Expression in Insects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. Immune barriers to successful gene therapy10.1016/j.molmed.2008.11.005 ↗
2. Promoters and control elements: designing expression cassettes for gene therapy10.2174/1566523044578077 ↗
3. Percutaneous methods of vector delivery in preclinical models10.1038/gt.2012.14 ↗
4. Tissue engineering via local gene delivery10.1007/s001090000118 ↗
5. Local gene delivery for cancer therapy10.2174/156652311797415854 ↗
6. Local delivery of matrix metalloproteinase gene prevents the onset of renal sclerosis in streptozotocin-induced diabetic mice10.1089/10763270360728206 ↗
7. Gene therapy for cardiovascular diseases10.2174/1381612043453379 ↗
8. Current status of catheter- and stent-based gene therapy10.1016/j.cardiores.2004.07.003 ↗
9. Site specific gene delivery in the cardiovascular system10.1016/j.jconrel.2005.09.031 ↗
10. Microarrays of cells expressing defined cDNAs10.1038/35075114 ↗
11. Surface immobilization of hexa-histidine-tagged adeno-associated viral vectors for localized gene delivery10.1038/gt.2010.81 ↗
12. Surface-tethered DNA complexes for enhanced gene delivery10.1021/bc015575f ↗
13. Controlled release systems for DNA delivery10.1016/j.ymthe.2004.03.020 ↗
14. Coronary–artery stents10.1056/NEJMra051091 ↗
15. Heart disease and stroke statistics—2011 update: a report from the American Heart Association
16. Coronary artery restenosis: vascular biology and emerging therapeutic strategies10.1586/14779072.4.4.543 ↗
17. Gene therapy for restenosis – what now, what next?10.2174/1566523043346435 ↗
18. Gene therapy for restenosis: biological solution to a biological problem10.1016/j.yjmcc.2006.11.012 ↗
19. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys10.1161/ATVBAHA.107.154609 ↗
20. Gene delivery from a DNA controlled-release stent in porcine coronary arteries10.1038/81176 ↗
21. Stent-based local delivery of nuclear factor-kappaB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits10.1161/CIRCULATIONAHA.105.582254 ↗
22. DNA delivery from an intravascular stent with a denatured collagen–polylactic–polyglycolic acid-controlled release coating: mechanisms of enhanced transfection10.1038/sj.gt.3302043 ↗
23. Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis10.1161/ATVBAHA.109.186429 ↗
24. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis10.1161/01.CIR.0000133324.38115.0A ↗
25. Anti-DNA antibody modified coronary stent for plasmid gene delivery: results obtained from a porcine coronary stent model10.1002/jgm.1529 ↗
26. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents10.1073/pnas.0502945102 ↗
27. Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries10.1161/CIRCULATIONAHA.107.746412 ↗
28. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries10.1161/01.ATV.0000157582.33180.a9 ↗
29. Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus10.1089/10430340252792576 ↗
30. Gene-eluting stents: comparison of adenoviral and adeno-associated viral gene delivery to the blood vessel wall in vivo10.1089/hum.2006.17.741 ↗
31. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis10.1038/mt.2008.165 ↗
32. Gene-eluting stents: non-viral, liposome-based gene delivery of eNOS to the blood vessel wall in vivo results in enhanced endothelialization but does not reduce restenosis in a hypercholesterolemic model10.1038/gt.2011.92 ↗
33. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo10.1089/10430349950018021 ↗
34. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields10.1073/pnas.0909506107 ↗
35. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents10.1073/pnas.0708338105 ↗
36. Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells10.1089/hum.1998.9.3-367 ↗
37. Validation of kinetics similarity in qPCR10.1093/nar/gkr778 ↗
38. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB195410.1002/jgm.795 ↗
39. Tissue engineering of urethra using human vascular endothelial growth factor gene-modified bladder urothelial cells10.1111/j.1525-1594.2007.00502.x ↗
40. The road to biological pacing10.1038/nrcardio.2011.120 ↗
41. Delivery of large biopharmaceuticals from cardiovascular stents: a review10.1021/bm700540p ↗
42. Release of plasmid DNA from intravascular stents coated with ultrathin multilayered polyelectrolyte films10.1021/bm0604808 ↗
43. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model10.1016/j.cardiores.2004.04.029 ↗
44. Rat arterial wall retains myointimal hyperplastic potential long after arterial injury10.1161/01.CIR.96.4.1291 ↗
45. Transgene delivery of plasmid DNA to smooth muscle cells and macrophages from a biostable polymer-coated stent10.1038/sj.gt.3302010 ↗
46. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries10.1161/01.CIR.94.7.1690 ↗
47. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions10.1089/10430340050111368 ↗
48. Inflammation and restenosis in the stent era10.1161/01.ATV.0000037100.44766.5B ↗
49. Interpretation of protein adsorption: surface-induced conformational changes10.1021/ja042898o ↗
50. Biocompatibility of cardiovascular gene delivery catheters with adenovirus vectors: an important determinant of the efficiency of cardiovascular gene transfer10.1006/mthe.2000.0059 ↗
51. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities10.1016/S0169-409X(02)00179-5 ↗